A Phase 1 Study of LY2874455 in Participants With Advanced Cancer

Phase 1 Completed 94 enrolled Eli Lilly and Company

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study is to determine the recommended Phase 2 regimen of study drug that may be safely administered to participants with advanced and or metastatic cancer. The study consists of two parts: a dose escalation and a dose confirmation.

Timeline

Start: 2010-12
Primary completion: 2014-08
Completion: 2015-02

Publications

Michael M, Bang YJ, Park YS, Kang YK, Kim TM, Hamid O, Thornton D, Tate SC, Raddad E, Tie J. A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Target Oncol. 2017 Aug;12(4):463-474. doi: 10.1007/s11523-017-0502-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2874455	Small molecule	2 mg	Oral
Subject	LY2874455	Small molecule	4 mg	Oral
Subject	LY2874455	Small molecule	8 mg	Oral
Subject	LY2874455	Small molecule	10 mg	Oral
Subject	LY2874455	Small molecule	14 mg	Oral
Subject	LY2874455	Small molecule	16 mg	Oral
Subject	LY2874455	Small molecule	18 mg	Oral
Subject	LY2874455	Small molecule	24 mg	Oral

A Phase 1 Study of LY2874455 in Participants With Advanced Cancer

Summary

Timeline

Publications

Drugs

Indications